Why Biodesix, Inc.’s (BDSX) Stock Is Up 6.55%
As of Thursday, July 30, Biodesix, Inc.’s BDSX share price has surged by 6.55%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Commentary & Analysis
Why Biodesix, Inc.’s (BDSX) Stock Is Up 6.29%
As of Monday, July 27, Biodesix, Inc.’s BDSX share price has surged by 6.29%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Biodesix, Inc.’s (BDSX) Stock Is Up 5.38%
As of Friday, July 24, Biodesix, Inc.’s BDSX share price has surged by 5.38%, which has investors questioning if this is right time to sell.Michael Rose
Why Biodesix, Inc.’s (BDSX) Stock Is Up 10.31%
As of Wednesday, July 22, Biodesix, Inc.’s BDSX share price has surged by 10.31%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Biodesix, Inc.’s (BDSX) Stock Is Up 6.69%
As of Friday, June 26, Biodesix, Inc.’s BDSX share price has surged by 6.69%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | BDSX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $219.5 | $1,742.7 | 29% |
|
| Shares Out (Mil) | 9.7 | 76.7 | 20% |
|
| Institutional Ownership | 39.9% | 89.7% | 17% |
|
| Float (Mil) | 4.8 | 49.4 | 12% |
|
| Beta | 0.59 | 0.82 | 34% |
|
| Avg Daily Volume (000s) | 61 | 521 | 30% |
|
| Price Change (52-week) |
180.1% | 78.7% | 97% |
|
| Growth | BDSX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 14.2% | 11.0% | 71% |
|
| Net Income (5yr) | (2.4%) | (0.7%) | 36% |
|
| EPS (5yr) | 48.6% | 3.1% | 92 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (18.0%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BDSX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $96 | $1,456 | 26% |
|
| Net Income (TTM) (Mil) | ($32) | $12 | 20% |
|
| EPS (TTM) | ($3.926) | $0.300 | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($25) | $138 | 13% |
|
| Net Cash Flow (TTM) (Mil) | $8 | $8 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $71 | $316 | 42% |
|
| Enterprise Value (Q1) (Mil) | $204 | $2,170 | 26% |
|
| Valuation | BDSX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 23.56 | 2.85 | 96% |
|
| P/E | na | 26.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BDSX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 81.7% | 27.8% | 90% |
|
| Net Margin | (33.3%) | 1.1% | 14% |
|
| ROA | (35.3%) | 1.8% | 15% |
|
| ROE | (316.5%) | 7.1% | 2% |
|
| Liabilities to Assets | 90.4% | 59.9% | 86% |
|
| F-Score | 5 | 5 | 51% |
|
Biodesix, Inc. did not pass any screens on 7/31/2026.
